A diagnosis of pseudo-Cushing's syndrome using dexamethason/CRH and Alprazolam

Phase 2

Recruiting

• Conditions: Pseudo Cushing's Syndrome; Glucocorticoid , Stress, dexamethasone suppression test; D003480

• Registration Number: JPRN-jRCT1021210011
• Lead Sponsor: Asari Yuko

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-04-13
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

This study will be conducted in patients with both high basal ACTH and cortisol levels who have a cortisol level of >=3 mcg/dl on a 0.5 mg dexamethasone suppression test or have a midnight cortisol level of >=5 mcg/dl.

Exclusion Criteria

Those who are long-term user of steroids should be excluded.
In addition, if the blood glucose of patients is consistently above 300 mg/dl, they should be excluded because dexamethasone may exacerbate hyperglycemia.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ACTH, cortisol, salivary cortisol at midnight after administering alprazolam.<br>Early morning ACTH and cortisol the day after alprazolam oral administration followed by 0.5mg dexamethasone use.<br> ACTH and cortisol 15 minutes later after administering dexamethasone 0.5 mg every 6 hrs for a total of 8 doses, followed by CRH loading.

Secondary Outcome Measures

Name	Time	Method
rinary free cortisol in the early morning after administering alprazolam (spot urine)